UBS maintains Pfizer at Neutral, raises price target to $30 from $27

What happened

UBS kept its Neutral rating on Pfizer and raised its price target from $27 to $30. The new target is 11.1% higher than the previous target and implies 2.6% downside from Pfizer’s November 4 closing price of $30.79.

Confirmed

Global impact / market context

The higher target signals that UBS sees somewhat more value in Pfizer shares than before, but its Neutral rating indicates it does not view the shares as an obvious opportunity. The stated downside also shows the target remains slightly below the cited closing price.

Analyst inference

Five recent analyst notes over 30 days set Pfizer targets between $28 and $35, with UBS’s new $30 target within that range. This spread reflects differing analyst views and provides context, but does not establish how Pfizer’s business or shares will perform.

Confirmed

What to watch

1. Compare later analyst targets and ratings with UBS’s $30 target and the reported $28–$35 range to see whether views on Pfizer are converging or diverging. Analyst inference
2. Watch for company updates that could change expected sales or costs; the article provides no business results or explanation for UBS’s target increase. Analyst inference
3. The cited $30.79 November 4 close is above UBS’s target, which implies 2.6% downside; later share prices are not provided here. Confirmed

Evidence

• Original source link unavailable